Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1ccompared with multiple daily injections: a longitudinal follow-up study

التفاصيل البيبلوغرافية
العنوان: Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1ccompared with multiple daily injections: a longitudinal follow-up study
المؤلفون: Signe Rosenlund, Peter Rossing, Steen Andersen, Tine W. Hansen
المصدر: Diabetic Medicine. 32:1445-1452
بيانات النشر: Wiley, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Adult, Male, Risk, Insulin pump, medicine.medical_specialty, Denmark, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Urology, Renal function, Kidney, law.invention, Cohort Studies, chemistry.chemical_compound, Insulin Infusion Systems, Endocrinology, Randomized controlled trial, law, Diabetes mellitus, Internal Medicine, Albuminuria, Humans, Hypoglycemic Agents, Insulin, Medicine, Diabetic Nephropathies, Longitudinal Studies, Renal Insufficiency, Glycated Hemoglobin, Creatinine, business.industry, Middle Aged, medicine.disease, Confidence interval, Surgery, Diabetes Mellitus, Type 1, chemistry, Hyperglycemia, Disease Progression, Female, medicine.symptom, business, Follow-Up Studies
الوصف: Aim The effect of insulin pump [continuous subcutaneous insulin infusion (CSII)] treatment on diabetes complications in a modern clinical setting is largely unknown. We investigated the effect of 4 years CSII treatment on HbA1c, albuminuria and kidney function compared with multiple daily injections (MDI) in a single-centre clinical setting. Methods All patients initiating CSII treatment from 2004 to 2010 and followed for at least 4 years were included in the study: 193 people with Type 1 diabetes were matched (1 : 2) with 386 patients treated with MDI in the same period. Matching was based on diabetes duration, gender, HbA1c and normo-, micro- or macroalbuminuria at baseline. Urinary albumin/creatinine ratio (UACR) was measured yearly and annual change assessed from linear regression. Results CSII- vs. MDI-treated patients were comparable at baseline. After 4 years, HbA1c was 62 ± 11 vs. 68 ± 11 mmol/mol (7.8 ± 1.0 vs. 8.4 ± 1.0%) (P
تدمد: 0742-3071
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545b544e7d161f0329224ebf384063ddTest
https://doi.org/10.1111/dme.12950Test
حقوق: CLOSED
رقم الانضمام: edsair.doi.dedup.....545b544e7d161f0329224ebf384063dd
قاعدة البيانات: OpenAIRE